Sentence examples for more powerful study from inspiring English sources

Owing to development of more powerful study designs, the availability of dense marker maps, progress in high-throughput genotyping and a better basic understanding of the roles of genes in the immune system, this trend is likely to continue.

Similarly, Defendants and Professor Stulz offer no academic studies, independent testing or other support for their claim that any increased findings of statistical significance represent artificial inflation or bias as opposed to simply the more accurate findings of a more powerful study.

In addition to helping understand disease by providing more powerful study models, "what this technology would allow you to do is reprogram a skin cell, for example, from a Parkinson's patient... into a pluripotent cell and then in a petri dish redirect that cell into... a neuron" to treat that patient.

Although not significant, both augmentation index and ISI index was more favourable in the high MBL group, also suggesting a better arterial function in this group, and a more powerful study including more patients might confirm this association.

The effect sizes seen in ICAS and NCICAS were somewhat smaller but showed greater statistical significance because the studies included more children and had a more powerful study design (i.e., randomized, controlled trial) than did HEAL.

I showed that the combination of more powerful study designs and more accurate exposure assessment together with a better understanding of mechanisms of disease and the use, in the case of dioxins, of biomarkers of exposure, led to the strengthening of the epidemiological evidence.

Thus, further investigation is necessary to elucidate these dynamics, both in terms of study design and physiology, perhaps using more precise tools to assess diet or in more powerful studies of different design (e.g. intervention studies adequately powered to test gene treatment interactions).

Consequently, more powerful studies are needed to reach firmer conclusions on this matter.

Smaller studies will, therefore, scatter widely at the bottom, with larger, more powerful studies grouping more narrowly at the top.

Hence, even more powerful studies are required to study such joint effects reliably than to assess the relevance to CHD of arsenic alone.

Looking ahead, we would propose larger and more powerful studies on the use of ERCC1 as a cisplatin sensitivity biomarker as it is currently the most promising lead.